Company record · KLRS · Biological Products, (No Diagnostic Substances)
Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc.'s chief financial officer on the record is Liisa Bayko, effective July 20, 2026, per the filing record.
The record holds 1 verified CFO change for Kalaris Therapeutics, Inc. from Form 8-K filings, filed July 20, 2026 and the CFO signature on its 10-K filed March 17, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Liisa Bayko |
| Title as printed | Chief Financial Officer and Treasurer |
| Basis | Latest move: appointment, 8-K filed July 20, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-20Appointment
Kalaris Therapeutics, Inc. appoints Liisa Bayko as CFOeffective July 20, 2026 · 8-K filed July 20, 2026 · sec.gov, Item 5.02
2026-03-1710-K signature
Matthew Gall signed the annual report as Chief Financial Officer (Principal Financial Officer)
10-K filed March 17, 2026 · sec.gov
“/s/ Matthew Gall Chief Financial Officer March 17, 2026 Matthew Gall (Principal Financial Officer)”
Company
| Ticker | KLRS |
|---|---|
| SEC CIK | 0001754068 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-24 also names Matthew Gall alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-07-20, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.